Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE904.105.4 (+0.6 % )
PREV CLOSE (Rs.) 898.70
OPEN PRICE (Rs.) 909.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 790000
TODAY'S LOW / HIGH (Rs.)901.00 920.95
52 WK LOW / HIGH (Rs.)565.9 966
NSE904.05 5.45 (+0.61 % )
PREV CLOSE(Rs.) 898.60
OPEN PRICE (Rs.) 909.00
BID PRICE (QTY) 904.05 (1601 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 15048471
TODAY'S LOW / HIGH(Rs.) 900.80 921.00
52 WK LOW / HIGH (Rs.)565.6 966.35

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.07
Dividend Yield(%) 0.55
TTM EPS (Rs.) 30.61
P/E Ratio 29.54
Book Value (Rs.) 233.60
Face Value (Rs.) 2
MCap (Rs. in Mn) 729126.87
Price/Earning (TTM) 24.11
Price/Sales (TTM) 5.36
Price/Book (MRQ) 3.87
PAT Margin (%) 17.10
ROCE (%) 18.08
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
15May05-15-2021$Cipla reports 68% rise in Q4 consolidated net profit Cipla reports 68% rise in Q4

Cipla has reported results for fourth quarter and year ended March 31, 2021.

The company has reported a fall of 31.62% in its net profit at Rs 413.41 crore for the quarter under review as compared to Rs 604.57 crore for the same quarter in the previous year. Total income of the company decreased by 7.45% at Rs 3,282.45 crore for Q4FY21 as compared Rs 3,546.85 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 68.07% in its net profit attributed to shareholders at Rs 413.38 crore for the quarter under review as compared to Rs 245.95 crore for the same quarter in the previous year. Total income of the company increased by 4.41% at Rs 4,666.58 crore for Q4FY21 as compared Rs 4,469.37 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported a rise of 6.48% in its net profit at Rs 2,468.28 crore as compared to Rs 2,318.17 crore for the previous year. Total income of the company increased by 4.27% at Rs 14,130.86 crore for year under review as compared to Rs 13,552 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 55.50% in its net profit at Rs 2,404.87 crore as compared to Rs 1,546.52 crore for the previous year. Total income of the company increased by 11.15% at Rs 19,425.58 crore for year under review as compared to Rs 17,476.19 crore for year ended March 31, 2020.

Cipla has reported results for fourth quarter and year ended Ma..
10May05-10-2021$Cipla signs licensing agreement with Eli Lilly Cipla signs licensing agreem

Cipla has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic. Cipla will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla has signed a royalty-free, non-exclusive voluntary licens..
10May05-10-2021$Cipla informs about press release Cipla informs about press re

Cipla has informed that it has enclosed press release dated 10th May 2021 titled ‘Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India’.

The above information is a part of company’s filings submitted to BSE.

Cipla has informed that it has enclosed press release dated 10t..
10May05-10-2021$Cipla rises on signing licensing agreement with Eli Lilly Cipla rises on signing licen

Cipla is currently trading at Rs. 894.85, up by 11.90 points or 1.35% from its previous closing of Rs. 882.95 on the BSE.

The scrip opened at Rs. 890.20 and has touched a high and low of Rs. 896.00 and Rs. 877.70 respectively. So far 264748 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 966.00 on 20-Apr-2021 and a 52 week low of Rs. 565.90 on 15-May-2020.

Last one week high and low of the scrip stood at Rs. 924.00 and Rs. 869.55 respectively. The current market cap of the company is Rs. 71936.86 crore.

The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.

Cipla has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic. Cipla will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 894.85, up by 11.90 points or..
05May05-05-2021$Cipla jumps after its associate company incorporates wholly-owned subsidiary Cipla jumps after its associ

Cipla is currently trading at Rs. 888.80, up by 10.25 points or 1.17% from its previous closing of Rs. 878.55 on the BSE.

The scrip opened at Rs. 885.00 and has touched a high and low of Rs. 899.00 and Rs. 869.55 respectively. So far 598795 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 966.00 on 20-Apr-2021 and a 52 week low of Rs. 565.90 on 15-May-2020.

Last one week high and low of the scrip stood at Rs. 924.00 and Rs. 869.55 respectively. The current market cap of the company is Rs. 71872.34 crore.

The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.

Cipla’s associate company -- GoApptiv has incorporated a wholly-owned subsidiary company namely Iconphygital with effect from May 03, 2021. Iconphygital will be involved in the business of providing man-power staffing services.

ICONPHYGITAL has been incorporated with an objective to consolidate people engaged across various projects of GoApptiv as independent consultants or through third party service providers in a single entity. The move is expected to create right compliance framework, cultural ethos for managers, increase people loyalty and retention.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 888.80, up by 10.25 points or..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit4134.124682.8
Gross Profit 5531.8 33506.6
Operating Profit 6990.339518.4
Net Sales 32331.2139005.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Hester Biosciences (BSE)
 2470.05 (11.53%)
M.Cap ( in Cr)
2101.24
Astrazeneca Pharma I (BSE)
 3840.05 (2.70%)
M.Cap ( in Cr)
9600.13
Themis Medicare (BSE)
 497.30 (6.82%)
M.Cap ( in Cr)
456.94
Caplin Point Lab (BSE)
 591.05 (4.82%)
M.Cap ( in Cr)
4470.86
Glaxosmithkline Phar (BSE)
 1503.80 (1.65%)
M.Cap ( in Cr)
25475.28
Shareholding Pattern More
PROMOTERS 36.73 %
NON-INSTITUTION 22.84 %
FI/BANKS/INSURANCE 2.16 %
MUTUAL FUNDS/UTI 14.64 %
FII 0.01 %
GOVERNMENT 0 %
F & O Quotes